{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T23:06:56Z","timestamp":1740179216446,"version":"3.37.3"},"reference-count":23,"publisher":"Georg Thieme Verlag KG","issue":"01","license":[{"start":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T00:00:00Z","timestamp":1612569600000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Boehringer Ingelheim GmbH"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TH Open"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Objective\u2003Anticoagulation management in patients with atrial fibrillation (AF) and impaired renal function is challenging. This study aimed to evaluate anticoagulation prescription patterns in relation to renal function and to describe 2-year clinical outcomes among dabigatran users.<\/jats:p><jats:p>\n          Methods\u2003Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) is an international, prospective, and observational study program involving patients with newly diagnosed AF at risk for stroke. Prescription patterns were assessed by creatinine clearance (CrCl) at enrollment. Dabigatran users were followed for 2 years. Clinical outcomes were standardized for stroke and bleeding risk, based on CHA2DS2-VASc and HAS-BLED scores, with missing values imputed.<\/jats:p><jats:p>\n          Results\u2003Baseline CrCl values were available for 12,056 of 15,308 eligible patients (79%). With declining renal function, prescriptions increased for vitamin K antagonists (VKAs) and decreased for dabigatran (30\u201347% and 34\u201312%, respectively). The prescription of other non-vitamin K antagonists remained similar across CrCl groups (14\u201319%). In 4,873 dabigatran users, standardized stroke rates were low across all CrCl groups; 0.58\/100 patient-years (95% confidence interval [CI]: 0.30\u20130.90) in CrCl \u226580\u2009mL\/min, 0.85 (95% CI: 0.48\u20131.21) in CrCl 50 to 79\u2009mL\/min, and 0.33 (95% CI: 0.06\u20131.11) in CrCl 30 to 49\u2009mL\/min. Similarly, major bleeding rates were low and numerically increased with declining renal function (0.68\/100 patient-years, 95% CI: 0.39\u20131.03; 0.92, 95% CI: 0.58\u20131.32; and 1.26, 95% CI: 0.66\u20131.97, respectively).<\/jats:p><jats:p>\n          Conclusion\u2003In patients with AF, VKA prescriptions increased and dabigatran prescriptions decreased with declining renal function. Rates of stroke and major bleeding in dabigatran patients remained low across the categories of renal impairment.<\/jats:p>","DOI":"10.1055\/s-0040-1722706","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T21:50:18Z","timestamp":1612821018000},"page":"e35-e42","source":"Crossref","is-referenced-by-count":2,"title":["Anticoagulation Prescription and Outcomes in Relation to Renal Function in Patients with Atrial Fibrillation: Results from GLORIA-AF"],"prefix":"10.1055","volume":"05","author":[{"given":"Sake J.","family":"van der Wall","sequence":"additional","affiliation":[{"name":"Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Teutsch","sequence":"additional","affiliation":[{"name":"Department of CardioMetabolism and Respiratory Medicine, Boehringer Ingelheim International GmbH, Ingelheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio J.","family":"Dubner","sequence":"additional","affiliation":[{"name":"Electrophysiology Service, Cl\u00ednica y Maternidad Suizo Argentina, Buenos Aires, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Christoph","family":"Diener","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Duisburg-Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan L.","family":"Halperin","sequence":"additional","affiliation":[{"name":"The Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York City, New York, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang Sheng","family":"Ma","sequence":"additional","affiliation":[{"name":"Cardiology Department, Atrial Fibrillation Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth J.","family":"Rothman","sequence":"additional","affiliation":[{"name":"RTI Health Solutions, Research Triangle Institute, Research Triangle Park, North Carolina, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miney","family":"Paquette","sequence":"additional","affiliation":[{"name":"Department of Medicine, Boehringer Ingelheim, Burlington, Ontario, Canada; Global Epidemiology at Boehringer Ingelheim GmbH, Ingelheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Zint","sequence":"additional","affiliation":[{"name":"Global Epidemiology Department, Boehringer Ingelheim International GmbH, Ingelheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lionel Riou","family":"Fran\u00e7a","sequence":"additional","affiliation":[{"name":"Global Epidemiology Department, Boehringer Ingelheim International GmbH, Ingelheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shihai","family":"Lu","sequence":"additional","affiliation":[{"name":"Biostatistics and Data Sciences Department, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-1626","authenticated-orcid":false,"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom"},{"name":"Department of Clinical Medicine, Aalborg Thrombosis Research Unit, Aalborg University, Aalborg, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Menno V.","family":"Huisman","sequence":"additional","affiliation":[{"name":"Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the GLORIA-AF Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,2,6]]},"reference":[{"issue":"23","key":"ref1","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.jacc.2014.09.051","article-title":"Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study","volume":"64","author":"A N Bonde","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"08","key":"ref2","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1111\/j.1538-7836.2011.04347.x","article-title":"Incidence of chronic kidney disease in patients with atrial fibrillation and its relevance for prescribing new oral antithrombotic drugs","volume":"9","author":"J Kooiman","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1105594","article-title":"Stroke and bleeding in atrial fibrillation with chronic kidney disease","volume":"367","author":"J B Olesen","year":"2012","journal-title":"N Engl J Med"},{"issue":"04","key":"ref4","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1161\/01.STR.0000208294.46968.a4","article-title":"Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation","volume":"37","author":"E Birman-Deych","year":"2006","journal-title":"Stroke"},{"issue":"10","key":"ref5","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1177\/1060028014540868","article-title":"Appropriateness of prescribing dabigatran etexilate and rivaroxaban in patients with nonvalvular atrial fibrillation: a prospective study","volume":"48","author":"A S Larock","year":"2014","journal-title":"Ann Pharmacother"},{"issue":"06","key":"ref6","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1160\/TH11-11-0768","article-title":"Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients","volume":"107","author":"T Wilke","year":"2012","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref7","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","article-title":"2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: a Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons","volume":"140","author":"C T January","year":"2019","journal-title":"Circulation"},{"issue":"16","key":"ref8","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"J Steffel","year":"2018","journal-title":"Eur Heart J"},{"issue":"06","key":"ref12","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.chest.2015.12.029","article-title":"Major bleeding and hemorrhagic stroke with direct oral anticoagulants in patients with renal failure: systematic review and meta-analysis of randomized trials","volume":"149","author":"B H Raccah","year":"2016","journal-title":"Chest"},{"issue":"03","key":"ref13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ahj.2013.12.006","article-title":"Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation","volume":"167","author":"M V Huisman","year":"2014","journal-title":"Am Heart J"},{"issue":"12","key":"ref14","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.amjmed.2015.07.013","article-title":"Antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation: the GLORIA-AF Registry, Phase II","volume":"128","author":"M V Huisman","year":"2015","journal-title":"Am J Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ahj.2019.08.012","article-title":"Safety and effectiveness of dabigatran at 2 years: final outcomes from phase II of the GLORIA-AF registry program","volume":"218","author":"M Mazurek","year":"2019","journal-title":"Am Heart J"},{"issue":"23","key":"ref16","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1161\/CIR.0000000000000040","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society","volume":"130","author":"C T January","year":"2014","journal-title":"Circulation"},{"issue":"38","key":"ref17","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"P Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"S Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref19","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: Issues and guidance for practice","volume":"30","author":"I R White","year":"2011","journal-title":"Stat Med"},{"issue":"14","key":"ref20","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1002\/sim.7654","article-title":"Bootstrap inference when using multiple imputation","volume":"37","author":"M Schomaker","year":"2018","journal-title":"Stat Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"30271","DOI":"10.1038\/srep30271","article-title":"Glomerular filtration rate in patients with atrial fibrillation and 1-year outcomes","volume":"6","author":"G Boriani","year":"2016","journal-title":"Sci Rep"},{"issue":"21","key":"ref22","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","article-title":"Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial","volume":"123","author":"J W Eikelboom","year":"2011","journal-title":"Circulation"},{"issue":"09","key":"ref23","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.113.003628","article-title":"Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (randomized evaluation of long-term anticoagulation therapy) trial analysis","volume":"129","author":"Z Hijazi","year":"2014","journal-title":"Circulation"},{"issue":"04","key":"ref24","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2217\/fca-2019-0012","article-title":"Renal function and oral anticoagulant treatment of incident non-valvular atrial fibrillation: a retrospective study","volume":"15","author":"S V Ramagopalan","year":"2019","journal-title":"Future Cardiol"},{"issue":"06","key":"ref25","doi-asserted-by":"crossref","first-page":"e000535","DOI":"10.1161\/JAHA.113.000535","article-title":"Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation","volume":"2","author":"B A Steinberg","year":"2013","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"ref26","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"S J Connolly","year":"2009","journal-title":"N Engl J Med"}],"container-title":["TH Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0040-1722706.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T01:40:03Z","timestamp":1613612403000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0040-1722706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":23,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2021,1,13]]},"published-print":{"date-parts":[[2021,1]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0040-1722706","relation":{},"ISSN":["2512-9465"],"issn-type":[{"type":"electronic","value":"2512-9465"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}